Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma

Lenalidomide, a well-established drug for the treatment of multiple myeloma, significantly enhances patients’ survival. Previous clinical studies have demonstrated that its main side effect is an increased risk of thrombotic events. However, the underlying mechanism remains unexplored. Therefore, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Panpan, Xu, Bei, Xu, Jiadai, Xu, Yanyan, Wang, Yawen, Chen, Chen, Liu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532040/
https://www.ncbi.nlm.nih.gov/pubmed/37762399
http://dx.doi.org/10.3390/ijms241814097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532040/
https://www.ncbi.nlm.nih.gov/pubmed/37762399
http://dx.doi.org/10.3390/ijms241814097

Ejemplares similares